skip to content
Detailed Quote
5i Report

Review of Knight Therapeutics

SEP 19, 2018 - Specialty Pharmaceutical company focused on later stage commercialization of drugs. The company continues to hold on to a high balance of cash, waiting for the right opportunity. Despite strong fundamentals and management, the increased opportunity cost and stock trading sideways justify the rating to be downgraded one notch to 'B+'.

Download Report
Company Profile
Interactive Chart
Key Ratios
Top Banner 5i Free Trial
Analyst Recommendations
5i Recent Questions

Q: of all the companies listed, I currently have the same percentage of holding that is in the 5i portfolio. Which of these stocks would you be comfortable buying today and making it a 4-5 % holding as I have some cash and would like to average down. I am a young investor with a long horizon as these stocks are all in my RRSP.


Read Answer Asked by on October 09, 2018
CMS Buy Now
Share Information
News and Media